BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. Attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...
- Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related ...
Near-complete in vitro TTR stabilization was observed as early as day 28 and through completion of a 30-month study of patients with ATTR-CM. The Food and Drug Administration (FDA) has approved ...
A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...
BridgeBio received FDA approval for Attruby (acoramidis), a near complete TTR stabilizer (≥90%), approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients.
Attruby’s recent approval positions BBIO as a direct competitor to PFE’s Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback